Ceralasertib
Ceralasertib is an orally bioavailable ATR inhibitor with distinct pharmacokinetics from berzosertib. It induces replication catastrophe in ATM-deficient or replication stress-high tumours and synergises with PARP inhibitors, chemotherapy, and immunotherapy. Multiple clinical trials investigate it across ATM-mutant solid tumours and lymphomas in combination with olaparib and durvalumab.
Description
Scientific Overview: Ceralasertib is an orally bioavailable ATR inhibitor with distinct pharmacokinetics from berzosertib. It induces replication catastrophe in ATM-deficient or replication stress-high tumours and synergises with PARP inhibitors, chemotherapy, and immunotherapy. Multiple clinical trials investigate it across ATM-mutant solid tumours and lymphomas in combination with olaparib and durvalumab.
Mechanism of Action: ATR Kinase Inhibitor
Purity: ≥99% | Molecular Formula: C20H21ClN6O3S
For Research Use Only. Not intended for diagnostic, therapeutic, or clinical applications.
Additional information
| Effect | ATR Kinase Inhibitor |
|---|---|
| Purity | ≥99% |
| Molecular Formula | C20H21ClN6O3S |
| CAS Number | 1352226-88-0 |
